Pfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under the brand name Vyndaqel.
Pfizer gets U.S. approval for $225,000 a year heart drug
More from Industry NewsMore posts in Industry News »
- Sanofi and Translate Bio start clinical trial for mRNA flu vaccine
- Dr Reddy’s Laboratories launches Icosapent Ethyl Capsules in US
- Bharat Biotech’s Covaxin gets SEC approval on its Phase 3 trials efficacy data
- Covid-19 has highlighted the Indian pharma industry’s potential in transforming into an innovation hub: Sudarshan Jain